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ABSTRACT 30 
The objectives of present study were to assess the mucosal, cellular and humoral immune 31 
responses induced by two different infectious bronchitis virus (IBV) vaccination regimes and 32 
their efficacy against challenge by a variant IBV Q1. Day-old broiler chicks were vaccinated 33 
with live H120 alone (Group I) or in combination with CR88 (Group II).  Both groups were 34 
again vaccinated with CR88 at 14 days of age (doa). One group was kept as the control 35 
(Group III). A significant increase in lachrymal IgA levels was observed at 4 doa, which then 36 
peaked at 14 doa in the vaccinated groups. The IgA levels in group II were significantly 37 
higher than group I from 14 doa. Using immunohistochemistry to examine changes in the 38 
number of CD4+ and CD8+ cells in the trachea, it was found that overall patterns of CD8+ 39 
were dominant compared to CD4+ cells in both vaccinated groups.  CD8+ were significantly 40 
higher in group II compared to group I at 21 and 28 doa. All groups were challenged oculo-41 
nasally with a virulent Q1 strain at 28 doa, and their protection was assessed. Both vaccinated 42 
groups gave excellent ciliary protection against Q1, though group II’s histopathology lesion 43 
scores and viral RNA loads in the trachea and kidney showed greater levels of protection 44 
compared to group I. These results suggest that greater protection is achieved from the 45 
combined vaccination of H120 and CR88 of day-old chicks, followed by CR88 at 14 doa. 46 
Keywords: Infectious bronchitis virus, Chicken, Vaccination, Mucosal-humoral-cell 47 
mediated immune responses, Protection, Q1-challenge 48 
 49 
 50 
 51 
 52 
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INTRODUCTION 53 
The prevention of infectious bronchitis (IB) in chickens is achieved through the use of 54 
live and inactivated vaccines, which provide protection against virulent field IB viruses in the 55 
event of an exposure. Despite these preventative measures, outbreaks of IB frequently occur 56 
in many poultry producing countries (1-3). This is probably due to the emergence of new 57 
variants of infectious bronchitis virus (IBV) (1-5). For the successful protection of chickens 58 
against infection, it is essential to identify the prevalent genotypes in the region and to 59 
determine the cross-protective potential of available vaccines and optimise strategic 60 
vaccination programmes. 61 
IB was first described in the USA during the 1930s and was identified in the UK in 62 
1948. Thereafter, many IBV variants were isolated from Europe, significantly a variant called 63 
793B that emerged in the 1990s (6). Later, IBV QX was first identified in China (7) before 64 
spreading to Europe (8). Another IBV genotype, Q1, genetically and serologically distinct 65 
from the classical IBVs, was also reported in China (9), the Middle East (10) and Europe 66 
(11). To contain this strain, an effective vaccination programme is needed. However, very 67 
little is known about the cross protection induced by the commercially available vaccines or 68 
vaccination regimes against this variant Q1. 69 
An effective and long-lasting protection against IBV infection requires the activation 70 
of effector, memory cell-mediated and humoral immune responses against the virus (12). A 71 
number of studies have reported the systemic and local humoral immune response (HIR) to 72 
IBV vaccination (12-14). In chickens, experimentally challenged with IBV, the development 73 
of a cell mediated immune response (CMI) has been correlated with effective virus clearance, 74 
reduction of clinical signs and resolution of lesions (15, 16). The presence of cytotoxic CD8+ 75 
T lymphocytes (CTL) represents a good correlation for  decreasing infection and corresponds 76 
with a reduction in clinical signs, as CTL activity is major histocompatibility complex  77 
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restricted and these T cells mediate cytolysis (17). It has additionally been shown that the 78 
transfer of CTLs obtained from spleen of IBV-infected chickens, was protective to naïve 79 
chicks against a subsequent IBV challenge (15, 18). During the course of experimental viral 80 
infection, Kotani et al (2000) showed that the clearance of the IBV from the tracheal mucosa 81 
occurred at an early phase of the infection and CTLs at the tracheal mucosa were proposed to 82 
be involved in this clearance (19). To date, there is no information available on the tracheal 83 
mucosal leukocytes after vaccination with live IBV vaccines.  Nevertheless, Okino et al 84 
(2013) have quantified the relative expression of the CTLs genes in tracheal samples from 85 
vaccinated and further challenged birds. The up regulation of these genes, in the tracheal 86 
mucosa of the full-dose vaccinated birds, was significantly increased at 24 hours post 87 
infection (hpi), demonstrating the development of a CMI memory response (20). However, 88 
these researchers did not directly measure the activity of CMI, such as the cytotoxic 89 
mechanism of CTLs. 90 
Despite all these reports, the kinetics of, and the relationship between local and 91 
systemic HIR and CMI induced by different IBV vaccination regimes, needs to be better 92 
understood for protection against emerging IBV strains. Thus, the objective of our study was 93 
to measure the local as well as systemic HIR and CMI induced by two different IBV 94 
vaccination regimes  administered to commercial broiler chicks, and to estimate the 95 
protection achieved against a recently isolated virulent Q1 strain.   96 
 97 
MATERIALS AND METHODS 98 
Birds 99 
One hundred twenty broiler chicks, aged 1-day-old, were obtained from a commercial 100 
hatchery. Birds were allowed ad libitum access to feed and drinking water. All procedures 101 
were undertaken according to the UK legislation on the use of animals for experiments as 102 
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permitted under the project license PPL 40/3723, which was approved by the University of 103 
Liverpool ethical review committee.   104 
Challenge virus 105 
The virulent Q1 isolate used in this study was kindly provided by Merial Animal Health. 106 
PCR confirmed that the allantoic fluid, from eggs used to propagate the virus, was free of 107 
Newcastle disease, avian influenza, infectious bursal disease, infectious laryngotracheitis and 108 
avian metapneumoviruses. Q1 IBV was also free of bacterial or fungal contaminants. The 109 
virus was titrated in the chicken tracheal organ culture (TOC) as described before and 110 
expressed in 50% (median) ciliostatic doses (CD50)/ml (21). 111 
 112 
Vaccine preparation 113 
As recommended by the manufacturer (Merial Animal Health Limited, UK), the vaccines 114 
were prepared, by thoroughly mixing one vial of live IBV H120 (Bioral H 120®) vaccine with 115 
100 ml of sterile water (SW). For combined vaccinations, one vial of each Bioral H 120® and 116 
live IBV CR88 (GALLIVAC® IB88) vaccines were mixed together in 100 ml of SW. 117 
Immediately after preparation, the vaccines and SW were kept in a cold box (at 0°C). Each 118 
chick received a total of 100 μl of the appropriate vaccine ocularly (50 μl) and nasally (50 μl) 119 
or SW. To quantify the virus, titration of live IBV vaccine for H120 and CR88 was 120 
performed by using 9-11 days of age (doa) specific pathogen free (SPF) embryonated chicken 121 
eggs (ECE) inoculated via the allantoic cavity. The ECE were examined for IBV specific 122 
lesions (curling and dwarfing) of the embryos up to five days post inoculation. Viral titres 123 
were calculated according to Reed et al. (22) and expressed as the Egg infective dose 124 
(EID50/ml). The titre of the vaccine viruses used was 3.5 log10 EID50/chick and 4.25 log10 125 
EID50/chick for the H120 strain and CR88 strain, respectively. 126 
Experimental design 127 
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One hundred and twenty broiler chicks, aged 1-day-old, were divided into three groups 128 
(n=40 chicks/group) (Table 1). Chicks in Group I were inoculated oculonasally with 100 μl 129 
of live H120 vaccine alone. In group II, chicks were inoculated oculonasally with 100 μl of 130 
both live H120 and CR88 vaccines simultaneously. Chicks in both groups (I and II) were 131 
again inoculated with a live CR88 vaccine at 14 doa. Group III received only 100 μl of SW 132 
oculonasally and was kept as a control. Samples (5 birds/group) of serum, tears and 133 
heparinized blood were collected at 0, 4, 7, 14, 21 and 28 doa before sacrificing the birds. 134 
The tears and serum samples were stored at -20ºC, and blood samples were processed 135 
immediately for peripheral blood mononuclear lymphocytes isolation. Five chickens from 136 
each group per interval were humanely euthanized for the collection of approximately 1 cm 137 
of the upper trachea in OCT to be snap-frozen in liquid nitrogen for immunohistochemistry 138 
(IHC). The rest of the trachea was used for tracheal washes. At 28 doa, 10 birds from each 139 
group were challenged via ocular-nasal route with the Q1 (104.0 CD50/bird) and observed 140 
daily for clinical signs.  After 5 days post challenge (dpc), all 10 birds from each group were 141 
necropsied and tracheal samples were collected; a portion placed in the RNALater® (Qiagen, 142 
Crawley, UK) and stored at -70°C until processing for examination of viral RNA load. The 143 
remaining portions were examined by histopathology and cilliostasistests. The kidneys from 144 
all groups were also taken for histopathology and viral RNA load examination. 145 
 146 
Sample collection for antibody detection 147 
The potential of the vaccines to induce antibody production was assessed individually 148 
by using samples of sera, tears and tracheal washes.  Tears were collected using sodium 149 
chloride as described before (23), immediately centrifuged at 3000 x g for 3 min before 150 
storing the supernatant at -70°C until used. To collect the tracheal washes, the trachea was 151 
clamped with two artery forceps at both the ends, and washed with 1 ml PBS using a syringe 152 
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with 19 gauge needle (24). The collected samples were centrifuged at 3000 x g for 3 min, and 153 
the supernatant stored at -70°C until further use. 154 
ELISAs 155 
 To detect IBV antibodies, sera samples were tested with a commercial IBV ELISA kit 156 
(FlockChek®, IDEXX Laboratories, Inc, Westbrook, ME, USA), and immunoglobulin A 157 
(IgA) in tears and tracheal washes was assayed using commercial IgA chicken ELISA kit 158 
(Abcam, Cambridge, UK).  Both assays were carried out according to the respective 159 
manufacturer’s instructions. 160 
Haemagglutination inhibition (HI) test 161 
For the HI test, M41 and 793B HA antigens were obtained from GD Animal Health 162 
Service (Deventer, Netherlands). The Q1 HA antigen was prepared in our laboratory as 163 
described earlier (25). The HI test was conducted according to standard procedures (OIE), 164 
using 4 HA units of antigen per well. The HI titres were read as the reciprocal of the highest 165 
dilution showing complete inhibition and the HI geometric mean titres were expressed as 166 
reciprocal log2. 167 
Cellular immune responses 168 
Analysis of T lymphocyte subsets (CD4+:CD8+) ratio in peripheral blood 169 
To determine the percentage of T-lymphocyte subpopulations, blood was collected 170 
from the cephalic vein in heparin tubes (Sigma Aldrich Co., St. Louis, MO, USA) at final 171 
concentrations of 10 USP/ml of blood, and further diluted (1:1) with RPMI 1640 medium 172 
(Sigma Aldrich Co., St. Louis, MO, USA). The prepared blood samples (1 ml each) were 173 
then over layered onto 0.5 ml of Histopaque –1.077 gradient (Sigma Aldrich Co., St. Louis, 174 
MO, USA) and centrifuged in 1.5 ml Eppendorf vial at 8000 x g for 90 sec.  After 175 
centrifugation, the buffy coat formed of mononuclear cells was gently collected, washed 176 
twice with a RPMI 1640 medium and adjusted to 1×107 cells/ml. The cells were resuspended 177 
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in 0.5% BSA (Sigma Aldrich Co., St. Louis, MO, USA) in PBS (blocking solution) and 178 
incubated at room temperature for 15 min. The sample (100 μl) was incubated with 179 
antibodies against surface domains of CD4 (mouse anti-chicken CD4-FITC clone CT-4; 180 
0.5mg/ml; Southern Biotech, Birmingham, AL, USA) and CD8 (mouse anti-chicken CD8a-181 
FITC clone CT-8; 0.5mg/ml; Southern Biotech) receptors of T-lymphocytes (antibody final 182 
concentrations as 0.2 μl/100 μl of sample) for 30 min in the dark. The stained cells were 183 
detected by flow cytometry (BD Accuri® C6, BD Bioscience San Jose, CA, USA) to count 184 
the T lymphocytes. The unstained cell sample was used as a negative control to adjust the 185 
threshold. 186 
Immunohistochemical detection of CD4+, CD8+ and IgA-bearing B-cells in tracheal 187 
sections 188 
The OCT-embedded tracheal samples were cut into 5 μm sections, fixed in ice-cold 189 
acetone for 10 min, air dried at room temperature and stored at -80ºC until staining.  Just 190 
prior to staining, slides were removed from -80ºC and air dried at room temperature for 10 191 
min.  After endogenous peroxidase inhibition using 0.03% hydrogen peroxide in PBS for 20 192 
min, the endogenous biotin or biotin-binding proteins in tissue sections were blocked with 193 
blocking serum using VECTASTAIN® Elite ABC kit (Vector Laboratories, Burlingame, 194 
USA).  Following blocking, tissue sections were stained overnight at 4ºC in the dark to detect 195 
CD4+, CD8+  and IgA+ cells by using mouse monoclonal antibodies to chicken CD4 (clone 196 
CT-4; 0.5 mg/ml) and CD8a (clone CT-8; 0.5 mg/ml) at 1:1000, and to chicken IgA (clone A-197 
1; 0.5 mg/ml)  at 1:2000. All monoclonal antibodies were procured from Southern Biotech, 198 
Birmingham, AL, USA.  The staining procedure was performed as described earlier (26). For 199 
each sample, the average number of positive cells/400× microscopic field was calculated for 200 
each cell type (26). 201 
 202 
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Ciliary protection 203 
At 5 dpc, trachea samples were evaluated according to standard procedure for ciliary 204 
movement, and the ciliary protection for each group was calculated (27).  205 
Histopathological evaluation 206 
 At 5 dpc, kidneys and tracheas from humanely euthanized birds were collected and 207 
fixed in 10% formalin. The tissues were embedded in paraffin wax (50-60ºC) and sections 208 
were cut to 7μm thickness. Tissue sections were stained by haematoxylin and eosin (H&E) 209 
for microscopic evaluation, the scores attributed according to histopathological severity and 210 
determined by recommendations described previously (28, 29). 211 
Real time RT-PCR (RT-qPCR) 212 
Total RNA extractions from the tracheas and kidneys, collected from the challenged 213 
birds, were performed immediately using RNeasy® Mini Kit (Qiagen, Crawley, UK) 214 
according to the manufacturer’s instructions. Quantification of the viral RNA was done by 215 
quantitative real-time RT-PCR (RT-qPCR) using IBV 3’untranslated region (UTR) gene-216 
specific primers and probes as described previously (30). The RT-qPCR was performed 217 
according to the manufacturer’s instructions using the One-Step RT-PCR kit (Qiagen, 218 
Crawley, UK) and 40 ng of total RNA per reaction. Amplification plots were recorded and 219 
analyzed, the threshold cycle (Ct) determined with Rotor-Gene® Q thermocycler software 220 
(Qiagen, Crawley, UK). The Ct values were converted to log relative equivalent units (REU) 221 
of viral RNA, done through generation of  a standard curve of five 10-fold dilutions of 222 
extracted RNA from infective allantoic fluid of a 106 EID50 dose of M41 as described earlier 223 
(31).  224 
 225 
Statistical analysis 226 
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The comparisons of the means of anti-IBV antibody levels; CD4+:CD8+ ratio in peripheral 227 
blood; immunohistochemical detection of CD4+, CD8+ and IgA-bearing B-cells in tracheal 228 
sections were performed using one-way analysis of variance (ANOVA), followed by the 229 
post-hoc LSD multiple comparison test using GraphPad™ Prism version 6.00 software. 230 
Kruskal-Wallis test followed by Dunn’s test was used for statistical analysis of the non-231 
parametric RT-qPCR and histopathological evaluation data. Differences were considered 232 
significant at P<0.05. 233 
 234 
RESULTS 235 
Systemic humoral immune response 236 
ELISA 237 
On the day of vaccination, the mean of maternally derived anti-IBV antibody titre was 238 
1750±203. Subsequently, the antibody levels in all three groups declined to below cut-off 239 
point (396) by 14 doa. After the booster vaccination with the CR88 at 14 doa, a significant 240 
increase in the antibody titres till 28 doa was observed in groups I and II, as shown in Fig. 1. 241 
On these time points, the levels of antibodies were not significantly different between the 242 
vaccinated groups (P<0.05).  After 14 doa though, the antibody titres in group III was always 243 
less than the cut-off value of 396 in this assay. 244 
HI test 245 
The level of serotype specific antibodies against homologous and heterologous 246 
antigens was evaluated by a HI test (Table 2).  The HI antibody response against all the 247 
antigens used showed no significant difference (P<0.05) between the groups from 0 to7 doa. 248 
However, a lower antibody response was obtained in all groups when the antigen used in the 249 
HI test was heterologous (Q1) to the viruses used in the vaccination. On 14 doa, the mean HI 250 
antibody titre to the M41 was significantly higher (P<0.05) in group II than group I and III. 251 
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Thereafter, at 28 doa, the levels of antibodies to M41 in group I and II were very similar and 252 
significantly higher than group III (P<0.05). At 21 doa, group II showed significant increase 253 
of HI antibody response against CR88, following revaccination with a homologous antigen.  254 
A similar increase was observed in group I on the same sample day. Thereafter, at 28 doa, the 255 
HI antibody titre to CR88 antigen was overall significantly higher in group II (log2 8.2) 256 
followed by group I (log2 4.4) then group III (log2 1.8). At 21 doa, the titres to Q1 in groups I 257 
and II were higher compared to group III (P<0.05).  At 28 doa, the mean HI titre to Q1 was 258 
significantly higher (P<0.05) in group II than group I with a mean difference of 1.2 log2. 259 
Mucosal humoral immune responses 260 
In both, groups I and II, the level of IgA in tears increased significantly (P<0.05) 261 
compared to control group III from 4 doa, continuing to rise until and initially peaking on 14 262 
doa. In the vaccinated groups, after the second vaccination at day 14, IgA values fell, then 263 
increased slightly again through to 28 doa, the day of challenge. The IgA levels in group II 264 
were significantly higher (P<0.05) than group I from 14 doa until 28 doa, the end of the 265 
observation period (Fig. 2a). The level of IgA in tracheal washes in both vaccinated groups 266 
was detected from 4 doa, peaking at 7 doa before declining till 28 doa. No significant 267 
(P<0.05) difference in the level of IgA in tracheal washes induced by the two vaccine groups 268 
was observed at any doa (Fig. 2b). IgA levels in tears and tracheal washes of both vaccinated 269 
groups were significantly higher than the levels from the unvaccinated control group. 270 
Systemic cell-mediated immune response 271 
CD4+:CD8+ ratio in peripheral blood 272 
Flow cytometry results showed that at 7 doa, the CD4+:CD8+ ratios were slightly 273 
higher in both vaccinated groups compared to that of the non-vaccinated group, though there 274 
was no significant difference (P<0.05) between the CD4+:CD8+ ratios of the vaccinated and 275 
non-vaccinated groups observed up to 14 doa (Fig. 3).  After the booster vaccination with the 276 
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CR88 at 14 doa, the ratio of CD4+:CD8+ on 21 doa showed slight increase in both vaccinated 277 
groups, being significantly higher (P<0.05) in group I compared to that of group II and III.  278 
At 28 doa, the ratio was significantly higher (P<0.05) in group II compared to groups I and 279 
III. 280 
Mucosal cell-mediated immune responses in the trachea 281 
The kinetics of CD4+, CD8+ and IgA-bearing B lymphocytes in the trachea were 282 
studied by IHC (Fig. 4).  The number of CD4+ lymphocytes in the trachea increased 283 
significantly (P<0.05) from 4 doa in both vaccinated groups compared to the control (Fig. 284 
5a). The number of CD4+ cells reached its peak at 4 doa in group I and at 7 doa in group II, 285 
before gradually decreasing until 14 doa. After the second immunization, CD4+ cells 286 
strongly increased in number by 21 doa in comparison to the non-vaccinated controls before 287 
declining again. The difference between the vaccinated groups I and II was not statistically 288 
significant (P<0.05). The CD8+ cells subpopulation in groups I and II started to increase 289 
significantly (P<0.05) at 4 doa, reaching peak at 7 doa and then declining (Fig. 5b).  After 290 
revaccination with CR88 at 14 doa, both vaccinated groups showed a strong increase in the 291 
number of CD8+ cells. The number of CD8+ cells were significantly higher in group II than 292 
group I at 21 and 28 doa (P<0.05).  Overall, the dynamics of the CD8+ cell subpopulations in 293 
both vaccinated groups were more dominant than CD4+ cells.  At 7 doa, the IgA-bearing B 294 
cells increased in vaccinated groups I and II, peaking at 14 doa and showing significant 295 
difference compared with the unvaccinated group (P<0.05). The number of IgA-bearing B 296 
cells was significantly higher in group II than group I at 21 doa, whereas, no significant 297 
(P<0.05) difference was observed between both vaccinated groups at 28 doa (Fig. 4c).  298 
Protection 299 
After challenge, no clinical signs were observed in either vaccinated groups.  In the 300 
unvaccinated group, respiratory signs such as coughing, sneezing, head shaking, tracheal 301 
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rales and nasal discharge were observed until 5 dpc. The highest percentage of ciliary 302 
protection (97%) was observed in group II, followed by group I (89.75%). The unvaccinated 303 
challenged group (group III) showed little protection (12%) compared to the vaccinated 304 
challenged groups. 305 
Viral RNA loads, in all tracheal samples collected, were significantly higher (P<0.05) 306 
(4.416 log REU RNA) in the unvaccinated challenged group (III) compared to the vaccinated 307 
groups (I and II)as measured by real time RT-qPCR, at 5 dpc. The vaccinated groups, I and II 308 
showed mean log REU of viral RNA of 1.016 and 0.555, respectively, with no significant 309 
difference between these groups (Fig. 6).  Overall viral RNA in the kidney samples of all the 310 
groups were low compared to tracheal samples. The viral RNA load in kidneys in group III 311 
was significantly higher (P<0.05) than in group II, whereas, group I showed no significant 312 
difference (P<0.05) in log REU of viral RNA with either of group II and III. 313 
Histopathological lesions in tracheas and kidneys were induced by challenge virus in 314 
all the groups at 5 dpc. Marked histopathological changes occurred in group III (non-315 
vaccinated group) with mean scores of 10.2 and showed significant difference with group II 316 
(P<0.05), but not with group I (Fig. 7). The mean lesion scores for kidneys in group III was 317 
significantly higher (P<0.05) than group II, whereas, group I showed no significant 318 
difference (P<0.05) in mean lesion scores with either group II and III. However, overall 319 
mean lesion scores in kidneys were low compared to mean tracheal lesion scores. 320 
 321 
DISCUSSION 322 
 The vaccination regime, chosen in this study for group I, is based on the research 323 
demonstrating that improved protection was seen when two vaccines used were of different 324 
serotypes (27, 32). They also emphasized that the vaccination programme used in their 325 
experiments may not protect the respiratory tract against challenge with every new IBV 326 
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serotype to emerge. It is also evident that despite the use of Mass type vaccine at day 0, 327 
followed by 793B type vaccine at 14 doa (same as in group 1 in this study), significant 328 
number of new IBVs are still emerging under field conditions e.g. QX, IS/885/00, IS/1494/06 329 
and most recently Q1. Therefore, in order to optimize the use of currently available vaccines, 330 
to achieve better immunity and to assess protection against newly emerged Q1 strain, the 331 
vaccination regime for group II was also included in this work. 332 
At 1-day-old, chicks had high ELISA anti-IBV antibody titres in all groups, which 333 
declined and dropped to below the cut-off point by 14 doa.  In the groups that received the 334 
vaccine at one day old, these low antibody levels could result from the partial neutralization 335 
of the vaccine virus in the target tissues by the maternal antibodies present in the broilers at 336 
that age, with a consequently low replication of the vaccine virus and poor stimulation of the 337 
humoral response (16, 33, 34). Later, after the second vaccination at 14 doa, an increase in 338 
the antibody titres was observed until 28 doa (day of challenge) in groups I and II with no 339 
significant difference in antibody levels between these vaccinated groups (P<0.05).  HI 340 
antibody levels declined by 14 doa against the homologous and heterologous virus antigens, 341 
showing similar patterns to declining ELISA titres. Interestingly, by 28 doa, there was no 342 
significant difference between vaccinated groups I and II in terms of the level of antibodies to 343 
M41, whereas, the HI titres to 793B and Q1 were significantly higher in group II than group I 344 
(P<0.05). The role of antibody in the control of IBV infection remains controversial as 345 
workers have shown that circulating antibody titres did not correlate with protection from 346 
IBV infection (35-37). However, other studies demonstrated the importance of humoral 347 
immunity in disease recovery and virus clearance (38, 39). In our study, as expected, the 348 
higher HI titres were obtained using antigen homologous to vaccine strains. However, the 349 
chicks also appeared to be protected against heterologous challenge. This could be due to the 350 
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presence of local immunity of the upper respiratory tract, induced by vaccination thus 351 
reducing the replication of challenge virus.  352 
The role of IgA antibodies is important for mucosal immunity to IBV and its presence 353 
in tears following IBV antigen inoculation has been reported earlier (38, 40). In this study, a 354 
gradual increase in IgA levels were observed in tears for both vaccinated groups during the 355 
first two weeks after vaccination. These results are in agreement with previous research 356 
reporting similar kinetics of lachrymal fluid IgA production to H120 vaccination (20, 41). In 357 
addition, after the second vaccination, lachrymal IgA levels decreased in both vaccinated 358 
groups, though, the levels in group II remained significantly higher (P<0.05 ) than group I.  359 
This observation may indicate a decrease of lachrymal IgA levels after the second 360 
vaccination is most likely due to partial neutralization of the anti-IBV IgA. A sharp decrease 361 
of IgA-IBV in vaccinated chicks was also observed after challenge (42). In addition, no 362 
significant rise in specific lachrymal IgA of vaccinated chickens was detected after 363 
subsequent challenge with Ark-IBV isolate, explaining the probable role of neutralizing 364 
antibodies in the lachrymal fluid at the time of challenge (43). 365 
IBV-specific IgA can also be found in tracheal washes after an infection with strain of 366 
IBV M41 (39, 40). In this study, the pattern of IgA in tracheal washes in both vaccinated 367 
groups I and II was closely parallel, reaching peak at 7 doa and thereafter, declining till 28 368 
doa, suggesting a short duration of the local humoral immunity in the trachea.  Although 369 
there have been conflicting reports on the relative concentrations of IgA in the avian 370 
respiratory tract (44-46), our results are consistent with Hawkes et al (1983), which showed 371 
IgA antibodies in tracheal washes only at day 7 after vaccination (47).  Interestingly, in both 372 
vaccinated groups, the second vaccination did not cause any rise in tracheal IgA level.  373 
Similar findings have also been reported, revealing that the revaccination with homologous 374 
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IBV (M41 or H strains) (45), and secondary M41 IBV exposure (39),  did not induce the 375 
secondary secretary antibody response in tracheobronchial washings. 376 
Consistent with the notion that CMI is protective against IBV (18, 48), we next sought 377 
to study the level of systemic and local cellular immune responses.  CD4+ cells may directly 378 
produce antiviral cytokines, which increases B cell activity and promotes the proliferation, 379 
maturation, and functional activity of CD8+ CTLs, which plays a critical role in controlling 380 
IBV infection (49, 50). The ratio of CD4+:CD8+ has been widely shown to be indicative of 381 
the general immune system status (51, 52). In this study, the CD4+:CD8+ ratio showed no 382 
significant (P<0.05) variation among the groups till 14 doa. Nevertheless, the ratio at 28 doa 383 
was found significantly higher (P<0.05) in group II than in groups I and III indicating that 384 
second vaccination at 14 day-old in group II has probably enhanced the cellular immunity by 385 
promoting the differentiation and proliferation of CD4+ cells in peripheral blood. There is no 386 
specific data regarding the effects of different IBV vaccination on CD4+:CD8+ ratio in 387 
peripheral blood so as to compare the present findings, however, Yohannes et al. (2012) have  388 
reported significantly (P<0.05) higher CD4+:CD8+ ratio in IBV infected chicks than in the 389 
controls (53). In addition, the high CD4+:CD8+ ratio has also been associated with increased 390 
humoral incompetence in chickens, as a low CD4+:CD8+ ratio and a reduced response 391 
against sheep red blood cells have been reported earlier (54). In this study, significantly 392 
(P<0.05) higher HI titres at 28 doa to 793B and Q1 in group II than group I could be 393 
attributed to the high CD4+:CD8+ ratio in that group at that time point. However, the 394 
significance of this in relation to protection remains to be determined. 395 
The results of IHC in tracheal tissue showed that the number of CD4+ lymphocytes 396 
started increasing from 4 doa in both vaccinated groups, as compared to the control. At 28 397 
doa, no significant difference was reported between the vaccinated groups. The  CD8+ cells 398 
subpopulation in both vaccinated groups started to increase significantly (P<0.05) at 4 doa, 399 
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reaching peak at 7 doa and then declining in number until 14 doa, suggesting that infiltration 400 
and recruitment of these cells occurs in the first two week of initial IBV vaccination. Similar 401 
to the findings of the present study, in the trachea, CD8+ cells recruitment in response to 402 
infection were at a maximum by 7 days post infection (dpi) and CD4+ cells were not 403 
recruited until 5 dpi. This was reported by Dhinakar et al (1996) (55). This work also showed 404 
an overall higher infiltration of CD8+ cells in numbers compared to CD4+ cells in both 405 
vaccinated groups. This observation is consistent with a previous study (55), where CD8+ 406 
cells were also found to predominate compared to CD4+ cells in trachea after IBV infection. 407 
Moreover, the current study also documents significantly higher number of CD8+ cells in 408 
vaccinated chicks of group II compared to group I on 21 and 28 doa, respectively. The IgA-409 
bearing B cells in vaccinated groups reached peak at 14 doa, however, the number of these 410 
cells were significantly higher in group II in comparison to group I at 21 and 28 doa 411 
(P<0.05). This pattern of recruitment of B cells later than either class of T cells is in 412 
accordance with earlier studies (56, 57) who contended that local immunity against IBV is 413 
mediated mainly by T-cells. 414 
In this study, following the Q1 challenge, ciliary protection was higher in group II, 415 
vaccinated with mixed H120 and CR88 vaccines at day-old, than in group I, vaccinated at 416 
day old with H120 alone. Furthermore, the results of RT-qPCR showed that the viral RNA 417 
load at 5 dpc in the trachea, was higher in group I than group II although the difference was 418 
not statistically significant (P<0.05). In agreement with this, the scores of histopathology in 419 
the trachea showed that the damage caused by the Q1 was higher in group I than II and 420 
showed no significant difference in mean lesion scores with either of group II and III. On the 421 
basis of these tracheal histopathological assessment, chickens in group II were better 422 
protected compared with those in group I and this better protection might be attributed by 423 
various factors including those discussed below. 424 
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Although the anti-IBV ELISA antibody titre results indicated that there was no 425 
significant difference between the two vaccinated groups at the day of challenge, group II 426 
showed higher ciliary protection than group I. This observation is consistent with previous 427 
studies which have shown that circulating antibody levels were of minor importance in the 428 
protection of the respiratory mucosa against IBV challenge (14, 44).  429 
From our results, it appears that such overall higher protection could be due to 430 
significantly higher levels of CD8+ cells in the tracheal tissues in group II than group I at day 431 
of challenge. Previous study have shown that CD8+ cells are important contributors to viral 432 
clearance in respiratory virus infections, utilizing contact-dependent effector functions, IFN-γ 433 
and tumour necrosis factor-α (58). Therefore, we may speculate that the group II’s higher 434 
CD8+ cell reaction than the group I could have contributed to the faster viral clearance after 435 
challenge with Q1, explaining the differences between the vaccinated groups  in their tracheal 436 
protection. This possible explanation agrees with other studies that emphasized the 437 
involvement of local CD8+ cells in the infection of chickens with respiratory pathogens, such 438 
as Newcastle disease virus (59) and Mycoplasma gallisepticum (60). Additionally, group II’s 439 
higher levels of IgA in lachrymal fluid, compared to group I, could reduce the tracheal 440 
histopathological damage which also corroborates the hypothesis that the traditional role of 441 
IgA is to prevent pathogen entry at mucosal surfaces and neutralize virus in infected 442 
epithelial cells (61). IBV-specific IgA antibodies in lachrymal fluid were correlated with 443 
resistance to IBV reinfection (38, 40, 42). Our results are in agreement with a recent study by 444 
Okino et al (2013), in which the authors concluded that IBV IgA antibodies in lachrymal 445 
secretions and the expression of granzyme-A and CD8 genes in tracheal tissues after H120 446 
vaccination, provides a reliable approach to monitor immune protection status  in the trachea, 447 
as shown by examination for cilliostasis, histopathology and viral replication (20). For our 448 
study, we aimed to stain for a variety of cell-surface markers and thereby identify the T cell 449 
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populations infiltrating the trachea. This provides further information about the role of cell-450 
mediated immunity in protection given by different live IBV vaccination regimes against a 451 
novel IBV Q1 challenge. 452 
The results of RT-qPCR and scores of histopathology in the kidneys showed that the 453 
damage caused by the Q1 was higher in group I than II, and showed no significant difference 454 
in the mean lesion scores with either of group II and III. Specific cytotoxic T lymphocytes 455 
have been shown to be important for the systemic clearance of nephropathogenic IBV and 456 
reduction of kidney lesions (15). A plausible explanation is that a higher CD8+ cells response 457 
in the tracheal tissues (the portal of entry of challenge virus) in group II compared to group I 458 
could have prevented the challenge virus becoming viraemic thus failing to reach the kidneys. 459 
This provided an efficient prevention of kidney infection, as measured by viral RNA load and 460 
histopathological lesion scores in renal tissue.  461 
 462 
CONCLUSIONS 463 
Chicks vaccinated with H120 and CR88 at day-old, followed by CR88 at 14 doa, showed 464 
significantly higher CD8+ responses in the trachea and higher lachrymal IgA levels compared 465 
to those vaccinated with H120 alone. In terms of ciliary protection against Q1, though both 466 
vaccinated groups were protected, the combined vaccination of H120 and CR88 of day-old 467 
chicks, followed by CR88 at 14 doa, showed higher ciliary protection and less RNA load in 468 
trachea and kidneys, wherein histopathological lesions are reduced. This study highlighted 469 
the potential modulation of chick immune response with the use of currently available live 470 
vaccines so that better protection against variant IBVs can be afforded.  471 
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Fig. 1. Anti-infectious bronchitis virus (IBV) antibody titres of the different groups 646 
vaccinated with a live H120 alone (group I) or in combination with CR88 (group II) at day-647 
one.  Both groups were again vaccinated with CR88 at 14 days of age. One group (group III) 648 
was kept as control. Where values were significantly (P<0.05) different these are shown with 649 
different letters and all other values were not significantly (P<0.05) different between the 650 
groups on those sampling points. 651 
 652 
 653 
Fig. 2. Detection of IgA production using ELISA in (a) tears (b) tracheal wash of chickens 654 
(n=5 per group) vaccinated with a live H120 alone (group I) or in combination with CR88 655 
(group II) at day-one.  Both groups were again vaccinated with CR88 at 14 days of age. One 656 
group (group III) was kept as control. The IgA antibody levels in tears and tracheal wash 657 
from control chickens (group III) remained below the detectable level. Asterisks indicate 658 
values between the two vaccine groups were significantly different (P<0.05) on those time 659 
point. Error bars indicate standard error of the mean. 660 
 661 
 662 
Fig. 3. The ratio of CD4+:CD8+analyzed by flow cytometry in peripheral blood of chickens 663 
vaccinated with a live H120 alone (group I) or in combination with CR88 (group II) at day-664 
one.  Both groups were again vaccinated with CR88 at 14 days of age. One group (group III) 665 
was kept as control. Depicted are the mean values (n=5 per group) and one standard error. 666 
Where values were significantly (P<0.05) different these are shown with different letters and 667 
all other values were not significantly (P<0.05) different between the groups on those time 668 
point.  669 
 670 
 671 
Fig. 4. Immunohistochemical detection of CD4+ cells in group II at 28 days of age (B), 672 
CD8+  cells  in group II at 28 days of age (C), IgA-bearing B-cells group II at 28 days of age 673 
(D), in tracheas of chickens vaccinated with live H120 alone (group I) or in combination with 674 
CR88 (group II) at day-one.  Both groups were again vaccinated with CR88 at 14 days of 675 
age. One group (group III) was kept as control (A). Magnification (400x). Arrows indicate 676 
positive cells. 677 
 678 
 679 
Fig. 5. Summary of CD4+ cells (a), CD8+ cells (b), and IgA-secreting cells (c) determined by 680 
immunohistochemical staining in the trachea  of chickens vaccinated with a live H120 alone 681 
(group I) or in combination with CR88 (group II) at day-one.  Both groups were again 682 
vaccinated with CR88 at 14 days of age. One group (group III) was kept as control. Depicted 683 
are the mean values (n=5 per group) and one standard error. Where values were significantly 684 
(P<0.05) different these are shown with different letters and all other values were not 685 
significantly (P<0.05) different between the groups at those time points.  686 
 687 
 688 
 689 
 690 
 691 
 692 
 693 
 694 
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Fig. 6. Quantification of infectious bronchitis virus (IBV) expressed as log REU of RNA, in 695 
trachea and kidney measured by real time RT-PCR after 5 dpc from chickens experimentally 696 
challenged at 28 days of age with Q1 strain of IBV (n=10 per group). The chickens were 697 
previously vaccinated with a live H120 alone (group I) or in combination with CR88 (group 698 
II) at day-one.  Both groups were again vaccinated with CR88 at 14 days of age. One group 699 
(group III) kept as control received sterile water. Significant differences between the groups 700 
were detected by Kruskal-Walis test followed by Dunn’s mean test indicated with different 701 
letters (P<0.05). 702 
 703 
Fig. 7. Means of histopathological scores of lesions in trachea and kidney samples after 5 dpc 704 
from chickens experimentally challenged at 28 days of age with Q1 strain of infectious 705 
bronchitis virus (n=10 per group). The chickens were previously vaccinated with a live H120 706 
alone (group I) or in combination with CR88 (group II) at day-one.  Both groups were again 707 
vaccinated with CR88 at 14 days of age. One group (group III) kept as control was inoculated 708 
with sterile water. Significant differences between the groups were detected by Kruskal-709 
Wallis test followed by Dunn’s mean test indicated with different letters (P<0.05) 710 
 711 
 712 
 713 
 714 
Table 1:  Study design showing groups, vaccine and vaccination regimes.  At 28 day of age, 715 
10 chicks from each group were challenged with a virulent IBV Q1.  716 
 717 
 718 
IBV vaccine 
(dosage/chick in 100 μl) 
 
Group/days of age 
 
I II III 
0 14 0 14 0 14 
H120 
(3.5 log10 EID50) √  √ √   
CR88 
(4.25 log10 EID50)  
 
√  √   
Sterile water  
(SW)     
 
√ 
 
 
√ 
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Table 2. Geometric mean anti-IBV HI antibody titre (log2) in serum of chickens vaccinated with live H120 alone (group I) or in combination 719 
with CR88 (group II) at day-one.  Both groups were again vaccinated with CR88 at 14 days of age. One group (group III) was kept as control. 720 
Significant differences between the groups (n=5 per group) for each homologous as well as heterologous antigen for each interval are 721 
represented by different letters (P<0.05) 722 
 723 
 724 
 725 
 726 
 727 
 728 
 729 
 730 
 731 
 732 
 733 
 734 
HI antigen Groups  Days of age 0 4 7 14 21 28 
M41 
Group I 9.2±0.374A 8.2±0.970A 7.4±0.400A 5±0.000B 5±0.548A 4±0.447A 
Group II 9.2±0.374A 8.8±0.374A 7.4±0.400A 6.4±0.510A 5.4±0.400A 4.4±0.400A 
Group III 9.2±0.374A 7.2±0.374A 6.4±0.748A 4.8±0.200B 4±0.632A 2±0.632B 
CR88 
Group I 8.4±0.400A 7.8±0.374A 6.8±0.490A 5±0.316A 6.8±0.583 A 4.4±0.678B 
Group II 8.4±0.400A 8.4±0.245A 6.8±0.374A 5.8±0.200A 7±0.548 A 8.2±0.583A 
Group III 8.4±0.400A 7.6±0.400A 7.4±0.245A 4.6±0.600A 3.4±0.245 B 1.8±0.490C 
Q1 
Group I 7±0.316A 3±0.316A 2.4±0.245A 2.2±0.200B 4.4±0.510 A 4.4±0.510B 
Group II 7±0.316A 3±0.678A 3.4±0.400A 3.8±0.374A 5±0.548A 5.6±0.245A 
Group III 7±0.316A 3.4±0.316A 2.2±0.200A 2±0.000B 2±0.000B 2±0.000C 
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